Literature DB >> 9069302

Conservative treatment by irradiation of epidermoid cancers of the anal canal: prognostic factors of tumoral control and complications.

D Peiffert1, P Bey, M Pernot, F Guillemin, E Luporsi, S Hoffstetter, P Aletti, P Boissel, M A Bigard, D Dartois, F Baylac.   

Abstract

UNLABELLED: We analyzed in a retrospective series of patients treated by conservative irradiation for an epidermoid cancer of the anal canal (ECAC) the prognostic factors of locoregional control (LRC), survival, late severe complications (LSC), and sphincter conservation (SC). METHODS AND MATERIALS: From 1976 until 1994, 118 patients presenting with an ECAC were conservatively treated (mean age, 65 years). According to the 1987 International Union Against Cancer (TNM) classification, they were: 19 T1, 70 T2, 22 T3, 7 T4, 94 N0, and 24 N1-3. The treatment started with external beam irradiation (EBI) (36 Gy in 3 weeks or 45 Gy in 5 weeks). Concomitant chemotherapy (5-fluorouracil and mitomycin C) was delivered to 31 patients. Two months later, a boost of 20 Gy was delivered by interstitial 192Ir brachytherapy to 101 patients and EBI in 5. Twelve other patients had an abdominoperineal resection (APR). The mean follow-up was 6 years.
RESULTS: At 5 years the overall survival was 60%, and specific survival (SS) was 75%; it was 94% for T1, 79% for T2, 53% for T3, and 19% for T4. In multivariate analysis, tumor size (> or = 4 cm), node involvement, and no response to the EBI were factors of poor prognosis for SS. Thirty-two locoregional recurrences occurred of which 21 were local recurrences in the 106 patients treated by a conservative schedule. Only tumor size and response to the EBI were prognostic factors on multivariate analysis for local and LRC. A total of 17 patients presented with LSC (Grade 3, 16 patients; and Grade 4, 1 patient), which was treated by APR in 4 patients and colostomy in 11 (of which 7 were definitive). The only significant prognostic factor for LSC in the multivariate analysis was the total extrapolated response dose of irradiation. The definitive rate of SC after conservative treatment in cured patients was 100% for T1, 82% for T2, 58% for T3, and 100% for T4. Since 1989, improvements of the technique have allowed reduction of the LSC in maintaining the same local control.
CONCLUSION: The results of this series are similar to those of the literature. The confirmation of pretherapeutic prognostic factors related to response to the treatment should allow us to adapt the therapeutic intensity for each case to obtain better tumor control, with as few sequelae as possible, to yield a better rate of SC.

Entities:  

Mesh:

Year:  1997        PMID: 9069302     DOI: 10.1016/s0360-3016(96)00493-2

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  14 in total

1.  Multimodal therapy of anal cancer added by new endosonographic-guided brachytherapy.

Authors:  J M Doniec; B Schniewind; G Kovács; V Kahlke; M Loehnert; B Kremer
Journal:  Surg Endosc       Date:  2006-01-21       Impact factor: 4.584

2.  Role of brachytherapy in the treatment of cancers of the anal canal. Long-term follow-up and multivariate analysis of a large monocentric retrospective series.

Authors:  Laëtitia Lestrade; Berardino De Bari; Pascal Pommier; Xavier Montbarbon; Emilie Lavergne; Jean-Michel Ardiet; Christian Carrie
Journal:  Strahlenther Onkol       Date:  2014-03-11       Impact factor: 3.621

3.  Management of Stage I Squamous Cell Carcinoma of the Anal Canal.

Authors:  Christy Y Chai; Hop S Tran Cao; Samir Awad; Nader N Massarweh
Journal:  JAMA Surg       Date:  2018-03-01       Impact factor: 14.766

Review 4.  Pooled Analysis of external-beam RADiotherapy parameters in phase II and phase III trials in radiochemotherapy in Anal Cancer (PARADAC).

Authors:  Eleonor Rivin Del Campo; Oscar Matzinger; Karin Haustermans; Didier Peiffert; Robert Glynne-Jones; Kathryn A Winter; Andre A Konski; Jaffer A Ajani; Jean-François Bosset; Jean-Michel Hannoun-Levi; Marc Puyraveau; A Bapsi Chakravarthy; Helen Meadows; John Northover; Laurence Collette; Melissa Christiaens; Philippe Maingon
Journal:  Eur J Cancer       Date:  2019-09-28       Impact factor: 9.162

5.  Radiotherapy with or without chemotherapy in the treatment of anal cancer: 20-year experience from a single institute.

Authors:  K Fakhrian; T Sauer; S Klemm; C Bayer; B Haller; M Molls; H Geinitz
Journal:  Strahlenther Onkol       Date:  2012-11-15       Impact factor: 3.621

6.  Prognostic factors derived from a prospective database dictate clinical biology of anal cancer: the intergroup trial (RTOG 98-11).

Authors:  Jaffer A Ajani; Kathryn A Winter; Leonard L Gunderson; John Pedersen; Al B Benson; Charles R Thomas; Robert J Mayer; Michael G Haddock; Tyvin A Rich; Christopher G Willett
Journal:  Cancer       Date:  2010-09-01       Impact factor: 6.860

7.  Higher radiation dose with a shorter treatment duration improves outcome for locally advanced carcinoma of anal canal.

Authors:  Kim Huang; Daphne Haas-Kogan; Vivian Weinberg; Richard Krieg
Journal:  World J Gastroenterol       Date:  2007-02-14       Impact factor: 5.742

8.  Impact of overall treatment time on survival and local control in patients with anal cancer: a pooled data analysis of Radiation Therapy Oncology Group trials 87-04 and 98-11.

Authors:  Edgar Ben-Josef; Jennifer Moughan; Jaffer A Ajani; Marshall Flam; Leonard Gunderson; JonDavid Pollock; Robert Myerson; Rani Anne; Seth A Rosenthal; Christopher Willett
Journal:  J Clin Oncol       Date:  2010-10-18       Impact factor: 44.544

9.  Clinical and Economic Evaluation of Treatment Strategies for T1N0 Anal Canal Cancer.

Authors:  Ashish A Deshmukh; Hui Zhao; Prajnan Das; Elizabeth Y Chiao; Yi-Qian Nancy You; Luisa Franzini; David R Lairson; Michael D Swartz; Sharon H Giordano; Scott B Cantor
Journal:  Am J Clin Oncol       Date:  2018-07       Impact factor: 2.339

10.  Anal cancer treated with radio-chemotherapy: correlation between length of treatment interruption and outcome.

Authors:  Stefan Janssen; Jürgen Meier zu Eissen; Gerd Kolbert; Michael Bremer; Johann Hinrich Karstens; Andreas Meyer
Journal:  Int J Colorectal Dis       Date:  2009-08-01       Impact factor: 2.571

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.